|
Generic Drugs Forum (GDF) 2026
|
|
1
|
84
|
March 24, 2026
|
|
Limit of Common or Small Nitrosamine Impurities in RSM irrespective of any particular MDD
|
|
9
|
306
|
January 21, 2026
|
|
Determination That ZANTAC (Ranitidine Hydrochloride) Injection, Equivalent to 25 Milligrams Base/Milliliter, Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness
|
|
1
|
245
|
December 17, 2025
|
|
FDA Approves Reformulated Ranitidine - Nitrosamine Impurities - NDMA
|
|
3
|
472
|
November 27, 2025
|
|
Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018β2025)-Pub
|
|
0
|
227
|
November 18, 2025
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
446
|
October 10, 2025
|
|
πΊπΈ FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
65
|
6052
|
October 3, 2025
|
|
US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2024
|
|
2
|
616
|
October 1, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
271
|
July 12, 2025
|
|
π¨ FDA deadline update
|
|
14
|
1314
|
August 7, 2025
|
|
AI limit for 1-Nitrosopiperazine
|
|
8
|
599
|
June 4, 2025
|
|
π
Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3614
|
May 2, 2025
|
|
π΅π» OTC Market Withdrawal of Diphenhydramine
|
|
0
|
650
|
April 24, 2025
|
|
FDA Generic Drugs Forum - Bioequivalence Approaches
|
|
2
|
1037
|
April 22, 2025
|
|
N-nitroso-esmolol
|
|
0
|
210
|
April 22, 2025
|
|
Generic Drugs Forum (GDF) 2025
|
|
5
|
1035
|
April 19, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
155
|
April 3, 2025
|
|
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
|
|
0
|
224
|
March 28, 2025
|
|
CDER Drug Safety Priorities Fiscal Year 2023
|
|
2
|
665
|
February 27, 2025
|
|
Impact of Antioxidant Excipients on N-nitrosamine Formation and Bioequivalence in Metformin Formulations - Pub
|
|
3
|
760
|
February 11, 2025
|
|
π¨βπ» FDA-CRCG NDSRI Workshop
|
|
2
|
1573
|
January 10, 2025
|
|
CHPA's response to the Control of Nitrosamine Impurities in Human Drugs rev.2
|
|
1
|
425
|
January 2, 2025
|
|
Requirement after reformulation of existing approved drug product for Europe
|
|
12
|
523
|
November 12, 2024
|
|
Aptarβs N-Sorb Nitrosamine Mitigation Solution Accepted to US FDAβs Emerging Technology Program
|
|
6
|
594
|
October 2, 2024
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
1
|
291
|
September 17, 2024
|
|
πΊπΈ FDA - Updated information on recommended AI for NDSRIs (23/Feb/2024) - Tables 2 & 3
|
|
16
|
4359
|
July 28, 2024
|
|
Pharmaceutical industry wants FDA to extend deadline for testing novel nitrosamines
|
|
3
|
1201
|
July 21, 2023
|
|
AI Limit for Nitroso Nebivolol
|
|
11
|
2908
|
April 3, 2024
|
|
Nitrosamine requirements for probiotics
|
|
4
|
372
|
February 12, 2024
|
|
N-nitroso Vonoprazan AI 96 ng/day- FDA
|
|
5
|
4186
|
January 29, 2024
|